RHHVF:OTC-Roche Holding AG (USD)

COMMON STOCK | Drug Manufacturers-General | OTC

Last Closing Price

USD 388.13

Change

0.00 (0.00)%

Market Cap

USD 339.36B

Volume

1.01K

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. The company has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors, as well as with Surface Oncology, Inc. to evaluate SRF388. It also has a clinical collaboration with Carrick Therapeutics, Ltd. to evaluate a novel combination of Carrick's samuraciclib and its giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-16 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
RHHBY Roche Holding AG

N/A

USD340.86B 22.27 15.09
RHHBF Roche Holding AG

N/A

USD336.19B 24.25 15.09
AZNCF AstraZeneca PLC

N/A

USD186.19B 41.30 22.57
NVSEF Novartis AG

N/A

USD184.54B 20.74 11.81
SNYNF Sanofi

N/A

USD123.95B 18.48 12.28
GLAXF GlaxoSmithKline plc

N/A

USD96.61B 16.18 11.84
CHGCF Chugai Pharmaceutical Co. Ltd

N/A

USD57.65B 28.35 0.17
CHGCY Chugai Pharmaceutical Co. Ltd

N/A

USD57.21B 28.13 0.17
BAYZF Bayer Aktiengesellschaft

N/A

USD55.43B 8.75 12.61
BAYRY Bayer Aktiengesellschaft

N/A

USD55.24B 8.67 12.61

ETFs Containing RHHVF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.49% 84% B 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.49% 84% B 54% F
Trailing 12 Months  
Capital Gain 13.39% 81% B- 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.39% 76% C 43% F
Trailing 5 Years  
Capital Gain 65.23% 72% C- 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.23% 72% C- 65% D
Average Annual (5 Year Horizon)  
Capital Gain 10.17% 73% C 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.17% 62% D- 43% F
Risk Return Profile  
Volatility (Standard Deviation) 13.51% 78% C+ 91% A-
Risk Adjusted Return 75.30% 81% B- 92% A-
Market Capitalization 339.36B 97% A+ 100% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.09 53% F 34% F
Price/Book Ratio 8.00 11% F 17% F
Price / Cash Flow Ratio 18.28 24% F 12% F
EV/EBITDA 15.09 14% F 23% F
Management Effectiveness  
Return on Equity 38.87% 100% A+ 95% A
Return on Invested Capital 32.04% 100% A+ 88% B+
Return on Assets 14.16% 89% B+ 96% A
Debt to Equity Ratio 28.12% 52% F 50% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.29 82% B- 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.